| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Zhang,Ming-Zheng | Chairman | 17.89% | MEDIGEN BIOTECHNOLOGY CORP. |
| Chen,Jin-Yan | Director | 17.89% | MEDIGEN BIOTECHNOLOGY CORP. |
| Chen,Can-Jian | Director | 0.17% | |
| Lin,Jia-Xiu | Director | 0.00% | |
| Wu,Ming-Yi | Independent Director | 0.00% | |
| Li,Yao-Ji | Independent Director | 0.00% | |
| Su,Peng-Fei | Independent Director | 0.01% |
Change Company Name to MEDIGEN VACCINE BIOLOGICS CORPORATION
2024/06/25
Change Person in Charge to Zhang,Ming-Zheng
2023/03/15
Change Company Name to HIGH-END VACCINE AND BIOLOGICAL PRODUCTS CO., LTD. (FORMER NAME: GYA VACCINE AND BIOLOGICAL PRODUCTS CO., LTD.)
2022/08/11
Change Capital to 5,000,000,000
2022/07/08
Change Capital to 3,000,000,000
2019/07/08
Change Company Name to MEDIGEN VACCINE BIOLOGICS CORPORATION
2017/06/07
Change Capital to 2,000,000,000
2015/12/15
Change Company Name to GYA VACCINE BIOLOGICS CO., LTD.
2015/05/07
Change Capital to 1,000,000,000
2014/01/20
下載完整報告查看完整數據
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 115,428 | 605,637 | 389,624 |
| Operating cost | 40,349 | 209,215 | 159,402 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 75,079 | 396,422 | 230,222 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 75,079 | 396,422 | 230,222 |
| Operating expenses | 107,953 | 542,088 | 1,444,051 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -32,874 | -145,666 | -1,213,829 |
| Non-operating income and expenses | 11,829 | 65,201 | 53,994 |
| Net profit (loss) before tax | -21,045 | -80,465 | -1,159,835 |
| Income tax expense (benefits) | 0 | 0 | 0 |
| Net profit (loss) of ongoing business for the current period | -21,045 | -80,465 | -1,159,835 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -21,045 | -80,465 | -1,159,835 |
| Other comprehensive profit (loss), net | -59,307 | 66,244 | -54,267 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -80,352 | -14,221 | -1,214,102 |
| Net profit (loss) attributable to owners of parent company | -21,045 | -80,465 | -1,159,835 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | -80,352 | -14,221 | -1,214,102 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | 0 | 0 | -3 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | -72,431 | 40,753 | -478,335 |
| Net cash inflows (outflows) from investing activities | -384,017 | 1,017,676 | 669,829 |
| Net cash inflow (outflow) from financing activities | -4,025 | -1,736,041 | 1,593 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 0 | 105 | -4,222 |
| Increase (decrease) in cash and cash equivalents in the current period | -460,473 | -677,507 | 188,865 |
| Beginning balance of cash and cash equivalents | 715,613 | 1,393,120 | 1,204,255 |
| Ending balance of cash and cash equivalents | 255,140 | 715,613 | 1,393,120 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 2,536,938 | 2,556,914 | 4,401,325 |
| Non-current asset | 1,730,530 | 1,806,992 | 1,691,321 |
| Total asset | 4,267,468 | 4,363,906 | 6,092,646 |
| Current liability | 201,150 | 214,218 | 1,991,711 |
| Non-current liability | 295,588 | 299,701 | 254,356 |
| Total liability | 496,738 | 513,919 | 2,246,067 |
| share capital | 3,287,491 | 3,287,491 | 3,286,081 |
| Equity - secruity token | - | - | - |
| capital reserve | 408,476 | 407,381 | 1,550,997 |
| retained earning | 39,975 | 61,020 | -1,018,350 |
| Other equity | 34,788 | 94,095 | 27,851 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 3,770,730 | 3,849,987 | 3,846,579 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 3,770,730 | 3,849,987 | 3,846,579 |
| Share capital awaiting retirement (unit: share) | - | - | - |
| Issued shares of advance equity (unit: shares) | 0 | 15,000 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 11 | 11 | 11 |
| 標案名稱 | 機關名稱 | 決標日期 | 決標金額 | 是否得標 |
|---|---|---|---|---|
| 「113年度四價流感疫苗」 | 衛生福利部疾病管制署 | 113/04/15 | 106671600.0 | 是 |
| 112年度四價流感疫苗採購案 | 衛生福利部疾病管制署 | 112/04/18 | 166951120.0 | 是 |
| 110年國內COVID-19疫苗緊急採購案 | 衛生福利部疾病管制署 | 110/05/28 | 4030000000.0 | 是 |
| 新竹科學工業園區新竹生物醫學園區景觀餐廳委託經營案 | 科技部新竹科學工業園區管理局 | 107/11/22 | 否 | |
| 「105年度甲醛不活化腸病毒71型B4亞型原液」 | 衛生福利部食品藥物管理署 | 105/11/07 | 否 |
